Esketamine (Spravato)
Esketamine (Spravato) explained
Esketamine (Spravato) is an intranasal NMDA receptor antagonist for treatment‑resistant depression and MDD with acute suicidal ideation/behavior; administered under REMS supervision.
FDA ApprovedEsketamine (Spravato) helps treat
• Treatment‑resistant depression (with oral antidepressant)
• MDD with acute suicidal ideation/behavior
additional medications
• Optimize oral antidepressants
• Psychotherapy
• ECT/TMS for refractory depression
medication risks
• Sedation and dissociation (boxed warnings)
• Transient BP increases
• Abuse/misuse potential
• Suicidality warning
side effects
• Dissociation
• Dizziness
• Nausea
• Increased blood pressure
• Somnolence
• Headache
FAQs
Q: How is esketamine given?A: As a supervised intranasal spray in a REMS program clinic.
Q: How fast does it work?
A: Some patients feel effects within hours; maintenance is required.
Q: Side effects session‑day?
A: Dissociation, increased BP, sedation—monitor for several hours.
Q: Abuse potential?
A: Schedule III—controlled access via REMS.
Q: Can I drive afterward?
A: No—avoid driving until the next day after restful sleep.